Your browser doesn't support javascript.
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
Guirakhoo, Farshad; Wang, Shixia; Wang, Chang Yi; Kuo, Hui Kai; Peng, Wen Jiun; Liu, Hope; Wang, Lixia; Johnson, Marina; Hunt, Adam; Hu, Mei Mei; Monath, Thomas P; Rumyantsev, Alexander; Goldblatt, David.
  • Guirakhoo F; Vaxxinity Inc, Dallas, Texas, USA.
  • Wang S; Vaxxinity Inc, Dallas, Texas, USA.
  • Wang CY; United Biomedical Inc Asia, Hsinchu, Taiwan.
  • Kuo HK; United Biomedical Inc Asia, Hsinchu, Taiwan.
  • Peng WJ; United Biomedical Inc Asia, Hsinchu, Taiwan.
  • Liu H; United Biomedical Inc Asia, Hsinchu, Taiwan.
  • Wang L; Vaxxinity Inc, Dallas, Texas, USA.
  • Johnson M; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Hunt A; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Hu MM; Vaxxinity Inc, Dallas, Texas, USA.
  • Monath TP; Vaxxinity Inc, Dallas, Texas, USA.
  • Rumyantsev A; Vaxxinity Inc, Dallas, Texas, USA.
  • Goldblatt D; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
J Infect Dis ; 226(8): 1401-1406, 2022 10 17.
Article in English | MEDLINE | ID: covidwho-2077781
ABSTRACT
The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis